Canada's Helus Pharma Q2 net loss widens on higher operating expenses
HELP•Helus Pharma reported a fiscal second-quarter net loss of C$103.10 million, wider year over year as operating expenses rose. It completed enrollment in its Phase 3 APPROACH study and expects topline data in Q4 2026.




